News

The West Australian – Proteomics achieves clinical validation for kidney test

A major clinical study involving 3,000 patients has validated ASX-listed Proteomics’ “PromarkerD” predictive test for diabetic kidney disease with the study confirming that PromarkerD has a high probability of predicting a clinical decline in kidney function up to four years in advance of it actually happening.

Article: Proteomics achieves clinical validation for kidney test

Subscribe
  • This field is for validation purposes and should be left unchanged.